Ligandrol-induzierte toxische Hepatopathie – ein Fallbericht

Zusammenfassung

Ein 37-jähriger Patient stellte sich mit schmerzlosem Ikterus und Juckreiz vor. Laborchemisch wurden ein Bilirubin 30-fach über dem oberen Normwert sowie eine leicht erhöhte Alanin-Aminotransferase (ALT) mit ansonsten geringfügig erhöhten Cholestaseparametern gesehen. Bei unauffälliger Umfelddiagnostik mit Ausschluss häufiger Ursachen einer Hepatitis wurde eine Leberbiopsie durchgeführt. Diese ergab eine kanalikuläre Cholestase mit Duktopenie und periportaler Fibrose. Erst nach wiederholter, eindringlicher Anamnese konnte ein Ligandrol-Abusus als Ursache für die Symptomatik ermittelt werden. Ligandrol wird als Selektiver-Androgen-Rezeptor-Modulator zur Förderung des Muskelaufbaus eingesetzt. Dieser Fall stellt keinen Einzelfall für den Missbrauch anaboler Substanzen im Amateursport dar.

Abstract

A 37-year-old man presented with painless jaundice and pruritus. Total Bilirubin was 30-fold the upper limit of normal (ULN), while ALT and further cholestasis parameters were found to be only slightly elevated. As comprehensive diagnostics showed no abnormal findings and ruled out frequent causes of elevated cholestasis markers, we performed a liver biopsy. The biopsy revealed canalicular cholestasis with ductopenia and periportal fibrosis. Only after a further and intensive anamnesis a ligandrol-abuse could be determined as cause for the symptoms. Ligandrol is misused as a selective androgen receptor modulator to promote muscle building. This case represents a typical case of abuse of anabolic substances in amateur sports.

Schlüsselwörter

DILI - Cholestase - Ligandrol - SARM

Keywords

DILI - Cholestasis - Ligandrol - SARM

Publication History

Received: 20 April 2022

Accepted after revision: 27 June 2022

Article published online:
18 October 2022

• Referenzen

• 1 Solomon ZJ, Mirabal JR, Mazur DJ. et al. Selective Androgen Receptor Modulators (SARMs) – Current Knowledge and Clinical Applications. Sex Med Rev 2019; 7: 84
• 2 Dalton JT, Barnette KG, Bohl CE. et al. The selective androgen receptor modulator GTx-024 (enobosarm) improves lean body mass and physical function in healthy elderly men and postmenopausal women: results of a double-blind, placebo-controlled phase II trial. J Cachexia Sarcopenia Muscle 2011; 2: 153
• 3 Gao W, Dalton JT. Expanding the therapeutic use of androgens via selective androgen receptor modulators (SARMs). Drug Discov Today 2007; 12: 241
• 4 Christiansen AR, Lipshultz LI, Hotaling JM. et al. Selective androgen receptor modulators: the future of androgen therapy?. Transl Androl Urol 2020; 9: S135
• 5 Bundesministerium für Justiz. AntiDopG – Gesetz gegen Doping im Sport. 2015 Accessed January 20, 2022 at: https://www.gesetze-im-internet.de/antidopg/BJNR221010015.html
• 6 Barbara M, Dhingra S, Mindikoglu AL. Ligandrol (LGD-4033)-Induced Liver Injury. ACG Case Reports J 2020; 7: e00370
• 7 Bedi H, Hammond C, Sanders D. et al. Drug-Induced Liver Injury From Enobosarm (Ostarine), a Selective Androgen Receptor Modulator. ACG Case Reports J 2021; 8: e00518
• 8 Flores JE, Chitturi S, Walker S. Drug-Induced Liver Injury by Selective Androgenic Receptor Modulators. Hepatol Commun 2020; 4: 450
• 9 Koller T, Vrbova P, Meciarova I. et al. Liver injury associated with the use of selective androgen receptor modulators and post-cycle therapy: Two case reports and literature review. World J Clin cases 2021; 9: 4062-4071
• 10 Chalasani NP, Hayashi PH, Bonkovsky HL. et al. ACG clinical guideline: The diagnosis and management of idiosyncratic drug-induced liver injury. Am J Gastroenterol 2014; 109: 950-966
• 11 Alvarez F, Berg PA, Bianchi FB. et al. International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis. J Hepatol 1999; 31: 929-938
• 12 Basaria S, Collins L, Dillon EL. et al. The Safety, Pharmacokinetics, and Effects of LGD-4033, a Novel Nonsteroidal Oral, Selective Androgen Receptor Modulator, in Healthy Young Men. Journals Gerontol Ser A Biol Sci Med Sci 2013; 68: 87
• 13 Levetiracetam. LiverTox Clin Res Inf Drug-Induced Liver Inj. 2019 Accessed January 18, 2022 at: https://www.ncbi.nlm.nih.gov/books/NBK548785/
• 14 Harb JN, Taylor ZA, Khullar V. et al. Rare cause of acute hepatitis: a common energy drink. BMJ Case Rep 2016;
• 15 Vivekanandarajah A, Ni S, Waked A. Acute hepatitis in a woman following excessive ingestion of an energy drink: A case report. J Med Case Rep 2011; 5: 1-3
• 16 Al Yacoub R, Luczkiewicz D, Kerr C. Acute kidney injury and hepatitis associated with energy drink consumption: A case report. J Med Case Rep 2020; 14: 1-4
• 17 Huang B, Kunkel D, Kabany M El. Acute Liver Failure Following One Year of Daily Consumption of a Sugar-Free Energy Drink. ACG Case Reports J 2014; 1: 214
• 18 Holmström P, Marmur J, Eggertsen G. et al. Mild iron overload in patients carrying the HFE S65C gene mutation: a retrospective study in patients with suspected iron overload and healthy controls. Gut 2002; 51: 723
• 19 Aranda N, Viteri FE, Montserrat C. et al. Effects of C282Y, H63D, and S65C HFE gene mutations, diet, and life-style factors on iron status in a general Mediterranean population from Tarragona, Spain. Ann Hematol 2010; 89: 767
• 20 Sahebjam F, Vierling JM. Autoimmune hepatitis. Front Med 2015 92 2015; 9: 187-219
• 21 Manns MP, Czaja AJ, Gorham JD. et al. Diagnosis and management of autoimmune hepatitis. Hepatology 2010; 51: 2193-2213
• 22 Androgenic Steroids – LiverTox – NCBI Bookshelf. Accessed April 01, 2022 at: https://www.ncbi.nlm.nih.gov/books/NBK548931/#!po=97.8261
• 23 Krishnan PV, Feng ZZ, Gordon SC. Prolonged intrahepatic cholestasis and renal failure secondary to anabolic androgenic steroid-enriched dietary supplements. J Clin Gastroenterol 2009; 43: 672-675
• 24 Zheng E, Sandhu N, Navarro V. Drug-induced Liver Injury Secondary to Herbal and Dietary Supplements. Clin Liver Dis 2020; 24: 141-155